| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer
|
Nishikawa, S.
|
|
|
27 |
12 |
p. 2300-2301
|
artikel
|
| 2 |
Antiangiogenic therapies in gastric cancer: trusting the pathway
|
Alsina, M.
|
|
|
27 |
12 |
p. 2141-2143
|
artikel
|
| 3 |
Antibody drug conjugates: lessons from 20 years of clinical experience
|
Tolcher, A.W.
|
|
|
27 |
12 |
p. 2168-2172
|
artikel
|
| 4 |
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC) †
|
Tai, W.M.
|
|
|
27 |
12 |
p. 2210-2215
|
artikel
|
| 5 |
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
|
Soria, J.C.
|
|
|
27 |
12 |
p. 2268-2274
|
artikel
|
| 6 |
Cancer-related financial toxicity: beyond the realm of drug pricing and out-of-pocket costs
|
Huntington, S.F.
|
|
|
27 |
12 |
p. 2143-2145
|
artikel
|
| 7 |
Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy
|
Ahmed, K.A.
|
|
|
27 |
12 |
p. 2288-2294
|
artikel
|
| 8 |
Editorial board
|
|
|
|
27 |
12 |
p. ii-iii
|
artikel
|
| 9 |
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia
|
Ladetto, M.
|
|
|
27 |
12 |
p. 2149-2160
|
artikel
|
| 10 |
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment
|
Voican, C.S.
|
|
|
27 |
12 |
p. 2172-2183
|
artikel
|
| 11 |
Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
|
Lawrence, N.
|
|
|
27 |
12 |
p. 2302-2303
|
artikel
|
| 12 |
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
|
Coyle, C.
|
|
|
27 |
12 |
p. 2184-2195
|
artikel
|
| 13 |
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
|
Genadieva-Stavrik, S.
|
|
|
27 |
12 |
p. 2251-2257
|
artikel
|
| 14 |
On the generalizability of prostate cancer studies: why race matters
|
Oren, O.
|
|
|
27 |
12 |
p. 2146-2148
|
artikel
|
| 15 |
Perspectives of health care professionals on cancer cachexia: results from three global surveys
|
Muscaritoli, M.
|
|
|
27 |
12 |
p. 2230-2236
|
artikel
|
| 16 |
Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer
|
Ferris, R.L.
|
|
|
27 |
12 |
p. 2257-2262
|
artikel
|
| 17 |
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial
|
Quidde, J.
|
|
|
27 |
12 |
p. 2203-2209
|
artikel
|
| 18 |
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial †
|
Yoon, H.H.
|
|
|
27 |
12 |
p. 2196-2203
|
artikel
|
| 19 |
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy
|
Moore, M.
|
|
|
27 |
12 |
p. 2216-2224
|
artikel
|
| 20 |
Reply to the letter to the editor ‘the clinical dilemma of grade 3 follicular lymphoma’ by Sorigue et al.
|
Klapper, W.
|
|
|
27 |
12 |
p. 2303-2304
|
artikel
|
| 21 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study
|
Kanda, S.
|
|
|
27 |
12 |
p. 2242-2250
|
artikel
|
| 22 |
Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group
|
Gronchi, A.
|
|
|
27 |
12 |
p. 2283-2288
|
artikel
|
| 23 |
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice
|
Michiels, S.
|
|
|
27 |
12 |
p. 2160-2167
|
artikel
|
| 24 |
Sustained response to salvage therapy for dabrafenib-resistant metastatic Langerhans cell sarcoma
|
Lorillon, G.
|
|
|
27 |
12 |
p. 2305-2307
|
artikel
|
| 25 |
Table of Contents
|
|
|
|
27 |
12 |
p. iv-vi
|
artikel
|
| 26 |
Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation †
|
Tinhofer, I.
|
|
|
27 |
12 |
p. 2262-2268
|
artikel
|
| 27 |
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy †
|
Perrone, F.
|
|
|
27 |
12 |
p. 2224-2229
|
artikel
|
| 28 |
Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient
|
Gastman, B.R.
|
|
|
27 |
12 |
p. 2304-2305
|
artikel
|
| 29 |
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
|
Sehouli, J.
|
|
|
27 |
12 |
p. 2236-2241
|
artikel
|
| 30 |
Validation and development of MTH1 inhibitors for treatment of cancer
|
Warpman Berglund, U.
|
|
|
27 |
12 |
p. 2275-2283
|
artikel
|
| 31 |
Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™)
|
Hagelstein, V.
|
|
|
27 |
12 |
p. 2294-2299
|
artikel
|
Tijdschrift beschrijving